In this week’s View, Dr. Eagle looks at what adult cardiologists should know about congenital heart disease patients. He then discusses sudden cardiac arrest and death in competitive and recreational ...

The following are key points to remember from a state-of-the-art review on cardiovascular (CV) risk in prostate cancer (PC): ...

What an amazing year 2024 was in terms of advances in cardiovascular care! With more than 882,000 users, ACC.org continues to be a critical resource for cardiovascular clinicians around the world! The ...

Early increases in CRP during immune checkpoint inhibitor (ICI) therapy are linked to a higher risk of venous thromboembolism (VTE). CRP trajectories could serve as biomarkers for assessing VTE risk ...

Multimodality imaging can identify papillary muscles that are the source of arrhythmias. Increased echogenicity, gadolinium enhancement, and calcifications on papillary muscles can indicate site of ...

The following are key points to remember from a review on nonsurgical management of chronic venous insufficiency (CVI): ...

In this interview, Clyde W. Yancy, MD, MACC, and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2024. Dr. Yancy discusses the FINEARTS-HF trial, the PREVENT calculator, the ...

Chlorthalidone is not superior to hydrochlorothiazide in preventing kidney disease progression in patients with hypertension. Chlorthalidone causes slightly more hypokalemia than hydrochlorothiazide.

The ACC has issued new guidance on practical approaches for arrhythmia monitoring after stroke, offering clinicians tailored strategies to improve post-stroke care by identifying and managing atrial ...

The TCW trial showed that in patients with severe aortic stenosis and complex CAD, FFR-guided PCI plus TAVI resulted in fewer deaths and major bleeding events compared with combined SAVR plus CABG at ...

In this week’s View, Dr. Eagle looks at the 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. He then discusses sex differences in ...

Highlighted text has been updated as of December 20, 2024. The SURMOUNT-1 trial showed that among patients with obesity, once-weekly tirzepatide reduced body weight substantially as compared to ...